ReviewInflammopharmacology2026
Navigating the maze of Alzheimer's: nimodipine and pioglitazone combination in the spotlight through inhibition of P2X7 dependent NLRP3 inflammasome activation.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation is considered to be a most vibrant molecular event in Alzheimer’s disease (AD) which is mainly triggered by accumulation of misfolded amyloid-β (Aβ) in neuronal cells. The Aβ mediated neuroinflammatory cascades further initiates the downstream neurodegenerative events through acceleration of microglial immune responses and oxidative stress persuaded mitochondrial dysfunction. The purinergic receptor, or P2X7 receptor, is measured as a pattern recognition element that is instantly activated by Aβ induced ATP release. This activation of P2X7 receptor further facilitates the NEK7-mediated NLRP3 activation. NLRP3 acts as a vital molecular mediator in the maturation of IL-1β and exacerbating the inflammatory responses in neurons. Along with inflammatory responses, Aβ also initiates Ca2+ influx-related mitochondrial toxicity, including Cyt-c release & ROS production. This dynamic neurotoxic pathway ultimately leads to neuronal cell death and exhibits severe neurodegeneration. Here, we hypothesized that Pioglitazone (PPAR-γ agonist) in combination with Nimodipine (L-type calcium channel blocker) may synergistically inhibit several steps in the P2X7 receptor-facilitated NLRP3 pathway and may possibly reduce the IL-1β production. Additionally, Nimodipine and Pioglitazone, were also reported to reduce the Aβ dependent Cyt-c release and ROS mediated mitochondrial biogenesis. This novel combination has the potential to attenuate the Aβ dependent detrimental cascades of AD along with their established protective mechanisms. Molecular docking studies further suggested potential interaction of Nimodipine and pioglitazone with P2X7 and NEK7 respectively suggesting the potential for these compounds, in addition to the known pharmacological activity discussed above, to influence inflammatory signal transduction. Therefore, Nimodipine and Pioglitazone can be a plausible combination to target the multifaceted AD pathogenesis and may represent a potential combination of AD therapy; however, the proposed mechanisms remain predictive and require systematic biochemical, cell-based and in-vivo validations.
Indexed as
Identifiers
41984340What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.